Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.34), $0.19 worse than the analyst estimate of ($0.15).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.